Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 21Carcinoma, Non-Small-Cell Lung 12Rectal Neoplasms 9Glioblastoma 9Esophageal Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Stomach Neoplasms 7Pancreatic Neoplasms 7Lung Neoplasms 6Head and Neck Neoplasms 6Colorectal Neoplasms 5Sarcoma 4Ovarian Neoplasms 4Neoplasms 4Fallopian Tube Neoplasms 4Colonic Neoplasms 3Brain Neoplasms 3Adenocarcinoma of Lung 3Urinary Bladder Neoplasms 2Osteosarcoma 2Melanoma 2Glioma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma 2Adenocarcinoma Of Esophagus 2Xerostomia 1Wilms Tumor 1Urethral Neoplasms 1Triple Negative Breast Neoplasms 1

Interventions

infigratinib 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Renal Pelvis and Ureter Urothelial Carcinoma × Surgical Procedures, Operative × Clear all
NCT04228042 2025-01-01

Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
15 enrolled 10 charts
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡